🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#CTS2024 Meet the Faculty for session #9: Retina Innovation 2024 & Beyond - An Investor View. Ram Palanki gathers insights from analysts, investors & industry. Panel includes Matthew Caufield, Emmett Cunningham, Anupam Dalal, Aaron Osborne, Ronil Patel, Kim Smith and Gena Wang.

#CTS2024 Meet the faculty for session #11: Designing Registration Trials with the Latest FDA Guidance. As part of their commitment to drug safety & efficacy, the U.S. FDA & its leadership have a long-standing history of being accessible accelerate innovation.

Novel MOAs & investigational drugs may require sponsors to develop new regulatory endpoints & clinical trial designs. Peter Kaiser will lead discussion with Arshad Khanani, Robert Kim, Eliot Lazar, Jennifer Lim, Raj Maturi, Steve Pakola, & Adam Turpcu on new FDA guidance

#CTS2024 #CTSRetina #Retina #nAMD #GeneTherapy #ClinicalTrials #ClinicalResearch #FDA

This weekend, we’re headed to Park City, UT, for Clinical Trials at the Summit. Leaders from our team will unite with experts on current clinical trials, the latest data and best practices. Don’t miss the presentations from Astellas leaders and retinal specialist, Dr. Chang, highlighted below!

#CTS2024 Meet the faculty for session #12: Gene Therapy and Optogenetics. Lejla Vajzovic, MD, FASRS will moderate a panel of investigators, clinician scientists, & industry to discuss PRISM, LUNA, and new entrants with insights on the future of #Genetherapy

Healio's coverage of #CTS2024 continues with real-world data investigating #aflibercept 8 mg from two #retina clinics across at least 6 months of follow-up 👀 Find out more 🔗 #OcularSurgeryNews #AMD #Ophthalmology Clinical Trials at the Summit healio.com/news/ophthalmo…

Two phase 3 trials are examining #sozinibercept combined with anti-VEGF-A therapies for #wetAMD in order to replicate superiority demonstrated in a previous trial, said @OptheaLimited's Fred Guerard 👇 #OcularSurgeryNews #retina #CTSretina Clinical Trials at the Summit healio.com/news/ophthalmo…

ANXV showed promise for #vision improvement in patients with retinal vein occlusion in a phase 2a study. Michael Singer, MD, discussed the results at Clinical Trials at the Summit. #OcularSurgeryNews #retina #ophthalmology Annexon Biosciences healio.com/news/ophthalmo…

Dual inhibition of the the Ang-2 and VEGF pathways with #faricimab may provide benefits such as reduced leakage, inflammation and fibrosis, Patricio Schlottmann, MD, told Healio at #CTSRetina. 🎥👇 #OcularSurgeryNews Clinical Trials at the Summit #Ophthalmology healio.com/news/ophthalmo…

Kester Nahen, PhD, of Notal Vision Monitoring Center, discusses the self-operated #AI-powered Scanly Home #OCT device, which recently received #FDA authorization. Full 🎥 below: #OcularSurgeryNews #Retina #Ophthalmology #CTS_Retina Clinical Trials at the Summit healio.com/news/ophthalmo…

In the CALM study, Yutiq for chronic noninfectious uveitis demonstrated: 👉A reduction in #uveitis flares. 👉Improved OCT. 👉Positive #IOP profile. Michael Singer, MD, shares the details from #CTS_Retina. #OcularSurgeryNews Alimera Clinical Trials at the Summit healio.com/news/ophthalmo…

A phase 3 trial of elamipretid for #dryAMD is targeting the new #FDA-approved endpoint of photoreceptor protection. Reenie McCarthy of Stealth BioTherapeutics spoke with Healio about the details 🔗 #ocularSurgeryNews #CTS_Retina Clinical Trials at the Summit healio.com/news/ophthalmo…

Ramanath Bhandari, MD, FASRS, of RevOpsis Therapeutics discusses the development of RO-104 for the treatment of retinal disease. 🔗 below #OcularSurgeryNews #Retina Clinical Trials at the Summit healio.com/news/ophthalmo…

🚨ICYMI🚨 Charles Semba, MD, of Eluminex Biosciences, discussed EB-105, trispecific antibody for #DME that targets VEGF-A, VEGF-B, placental growth factor, angiopoietin-2 and interleukin-6 receptor, at #CTS_Retina. 🔗👇 #OcularSurgeryNews Clinical Trials at the Summit healio.com/news/ophthalmo…

❗ NEW ❗ #Susvimo has reportedly shown positive data across three different phase 3 trials in #DR, #DME and neovascular #AMD. Carlos Quezada-Ruiz, MD, FASRS, discussed these results at #CTSRetina 👇 #OcularSurgeryNews Genentech Clinical Trials at the Summit healio.com/news/ophthalmo…

In the The SUMMIT study, the port delivery system showed a maintenance of #visualacuity and central subfield thickness, as well as a well-tolerated safety profile. Arshad Khanani discussed the details with Healio 👇 #CTSRetina Clinical Trials at the Summit Genentech healio.com/news/ophthalmo…

The phase 1/2a HORNBILL study indicated a potential disease-modifying effect of BI 764524 in eyes with diabetic macular ischemia. Read an overview of the results here 👇 #OcularSurgeryNews #Retina #CTS_Retina Clinical Trials at the Summit healio.com/news/ophthalmo…

A phase 3 program will investigate bel-sar delivered through a suprachoroidal injection and activated with a laser in patients with #choroidalmelanoma. Jill Hopkins, MD, of Aura Biosciences discusses the program 👇 #OcularSurgeryNews Clinical Trials at the Summit healio.com/news/ophthalmo…

We’re back! New location, same mission! Save the Date for the 2025 #CTSRetina Arshad Khanani